These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 18801095)
1. Methotrexate for psoriasis in the era of biological therapy. Warren RB; Chalmers RJ; Griffiths CE; Menter A Clin Exp Dermatol; 2008 Aug; 33(5):551-4. PubMed ID: 18801095 [TBL] [Abstract][Full Text] [Related]
2. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813 [TBL] [Abstract][Full Text] [Related]
3. Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies. Zachariae H Dermatology; 2005; 211(4):307-8. PubMed ID: 16286736 [No Abstract] [Full Text] [Related]
4. Liver biopsies and methotrexate: a time for reconsideration? Zachariae H J Am Acad Dermatol; 2000 Mar; 42(3):531-4. PubMed ID: 10688735 [No Abstract] [Full Text] [Related]
5. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Thomas JA; Aithal GP Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024 [TBL] [Abstract][Full Text] [Related]
6. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aithal GP; Haugk B; Das S; Card T; Burt AD; Record CO Aliment Pharmacol Ther; 2004 Feb; 19(4):391-9. PubMed ID: 14871278 [TBL] [Abstract][Full Text] [Related]
7. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271 [TBL] [Abstract][Full Text] [Related]
8. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Oogarah PK; Rowland PL; Mitchell DM; Smith A; Chalmers RJ; Rowan B; Haboubi NY Br J Dermatol; 1995 Oct; 133(4):512-8. PubMed ID: 7577576 [TBL] [Abstract][Full Text] [Related]
9. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254 [TBL] [Abstract][Full Text] [Related]
10. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Nijsten T; Spuls PI Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593 [No Abstract] [Full Text] [Related]
11. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate? Kaffenberger BH; Kaffenberger JA; Wong H; Jarjour W; Levin D; Bechtel MA Int J Dermatol; 2015 Jul; 54(7):752-6. PubMed ID: 26108262 [TBL] [Abstract][Full Text] [Related]
12. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Zachariae H; Heickendorff L; Søgaard H Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689 [TBL] [Abstract][Full Text] [Related]
13. Procollagen-3 N-terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications. van den Reek JMPA; Menting SP; Janssen WWL; Dhaliwal R; Heijboer AC; van Herwaarden AE; Sweep FCGJ; de Jong LM; Tjwa ET; Otero ME; Spuls PI; de Jong EMGJ Br J Dermatol; 2017 Nov; 177(5):1454-1457. PubMed ID: 28112796 [No Abstract] [Full Text] [Related]
14. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Mitchell D; Smith A; Rowan B; Warnes TW; Haboubi NY; Lucas SB; Chalmers RJ Br J Dermatol; 1990 Jan; 122(1):1-7. PubMed ID: 2297495 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. Carneiro SC; Cássia FF; Lamy F; Chagas VL; Ramos-e-Silva M J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969 [TBL] [Abstract][Full Text] [Related]
16. Methotrexate-induced liver cirrhosis in a patient of psoriasis. Avasthi G; Bhatt P; Singh J J Assoc Physicians India; 2012 May; 60():47-8. PubMed ID: 23029724 [TBL] [Abstract][Full Text] [Related]
17. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Bray AP; Barnova I; Przemioslo R; Kennedy CT Br J Dermatol; 2012 May; 166(5):1125-7. PubMed ID: 21967341 [No Abstract] [Full Text] [Related]
18. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Leon A; Nguyen A; Letsinger J; Koo J Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017 [TBL] [Abstract][Full Text] [Related]
19. Methotrexate hepatotoxicity: what is the evidence? Ahern MJ; Smith MD; Roberts-Thomson PJ Inflamm Res; 1998 Apr; 47(4):148-51. PubMed ID: 9628257 [No Abstract] [Full Text] [Related]
20. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis. Khan S; Subedi D; Chowdhury MM Postgrad Med J; 2006 May; 82(967):353-4. PubMed ID: 16679477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]